

Phase 1/2 Study of Vilastobart (XTX101), a Tumor-Activated, Fc-enhanced Anti-CTLA-4 Monoclonal Antibody, in Combination with Atezolizumab in Patients with Advanced Solid Tumors and in MSS CRC

J. Randolph Hecht¹, Diwakar Davar², Marwan Fakih³, Tanios Bekaii-Saab⁴, Nicholas Devito⁵, John George Knecht⁶, Andrae Lavon Vandross⁷, Cesar Augusto Perez⁸, Alberto Bessudo⁹, Anurag Gupta¹⁰, Sonali Garg¹⁰, Myra Popejoy¹⁰, Bruce Dezube¹⁰, Scott McConnell¹⁰, Katarina Luptakova¹⁰, Aparna Parikh¹¹, Sattanathan Paramasivan¹⁰, Sonali Garg¹⁰, Myra Popejoy¹⁰, Bruce Dezube¹⁰, Scott McConnell¹⁰, Katarina Luptakova¹⁰, Aparna Parikh¹¹, Sonali Garg¹⁰, Myra Popejoy¹⁰, Bruce Dezube¹⁰, Scott McConnell¹⁰, Katarina Luptakova¹⁰, Aparna Parikh¹¹, Sattanathan Paramasivan¹⁰, Sonali Garg¹⁰, Myra Popejoy¹⁰, Bruce Dezube¹⁰, Scott McConnell¹⁰, Katarina Luptakova¹⁰, Aparna Parikh¹¹, Sattanathan Paramasivan¹⁰, Sonali Garg¹⁰, Myra Popejoy¹⁰, Bruce Dezube¹⁰, Scott McConnell¹⁰, Katarina Luptakova¹⁰, Aparna Parikh¹¹, Sattanathan Paramasivan¹⁰, Sonali Garg¹⁰, Myra Popejoy¹⁰, Bruce Dezube¹⁰, Scott McConnell¹⁰, Katarina Luptakova¹⁰, Aparna Parikh¹¹, Sattanathan Paramasivan¹⁰, Sonali Garg¹⁰, Myra Popejoy¹⁰, Bruce Dezube¹⁰, Scott McConnell¹⁰, Katarina Luptakova¹⁰, Aparna Parikh¹¹, Sattanathan Paramasivan¹⁰, Sonali Garg¹⁰, Myra Popejoy¹⁰, Bruce Dezube¹⁰, Scott McConnell¹⁰, Katarina Luptakova¹⁰, Aparna Parikh¹¹, Sonali Garg¹⁰, Myra Popejoy¹⁰, Bruce Dezube¹⁰, Scott McConnell¹⁰, Sattanathan Paramasivan¹⁰, Sonali Garg¹⁰, Myra Popejoy¹⁰, Bruce Dezube¹⁰, Scott McConnell¹⁰, Sonali Garg¹⁰, Myra Popejoy¹⁰, Bruce Dezube¹⁰, Scott McConnell¹⁰, Sonali Garg¹⁰, Scott McConnell¹⁰, Scott McConnell (10) Xilio Therapeutics, Inc., Waltham, MA; (11) Massachusetts General Hospital, Boston, MA.

(1) UCLA Jonsson Comprehensive Cancer Center, Santa Monica, CA; (2) UPMC Hillman Cancer Center, Duarte, CA; (3) City of Hope Comprehensive Cancer Center, Durham, NC; (6) Tranquil Clinical Research, Webster, TX; (7) NEXT Oncology, Austin, TX; (8) Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona, Orlando, FL; (9) cCARE, Encinitas, CA; (1) UPMC Hillman Cancer Specialists - Lake Nona, Orlando, FL; (9) cCARE, Encinitas, CA; (1) UPMC Hillman Cancer Center, Duarte, CA; (2) UPMC Hillman Cancer Center, Duarte, CA; (3) City of Hope Comprehensive Cancer Center, Duarte, CA; (4) Mayo Clinic, Phoenix, AZ; (5) Duke University Medical Center, Duarte, CA; (4) Mayo Clinic, Phoenix, AZ; (5) Duke University Research, Webster, TX; (7) NEXT Oncology, Austin, TX; (8) Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona, Orlando, FL; (9) cCARE, Encinitas, CA;



- Intratumoral Treg depletion observed in a tumor biopsy from a MSS CRC patient was consistent with the intended mechanism of action of vilastobart
- Dose level of vilastobart 100 mg Q6W in combination with atezolizumab (1200 mg Q3W) was declared the initial RP2D
- Across all vilastobart dose levels (75-150 mg), minimal irAEs observed, colitis of any grade was experienced in 5% of patients (1 patient with Grade 3)
- No Grade 4 or 5 TRAEs at any dose level in Phase 1C



RESULTS OF PHASE 2 Combination of Vilastobart (100 mg Q6W) and Atezolizumab (1200 mg Q3W)

Phase 2 Enrolled Heavily Pre-Treated MSS Colorectal Cancer Patients With and Without Liver Metastases

Patient Characteristics	Total (N=40)	Patient Characteristics	Total (N=40)	Treatment Status
Demographics		Drien Lines of Anti Conser Treatment	Median 4	Continuing on Treatment
Age, median (range)	55 (25-82)	Prior Lines of Anti-Cancer Treatmen	(range 1-10)	Discontinued Treatment
Female	20 (50%)	unknown	2 (5%)	Disease Progression
ECOG PS 0	17 (43%)	1	5 (13%)	Clinical Progression
ECOG PS 1	23 (58%)	2	5 (13%)	Adverse Events
Tumor Types		3	7 (18%)	
MSS CRC	40	4	6 (15%)	70% of patients had 3 or more
Patients with liver metastases	16	5	7 (18%)	prior lines of treatment
Patients without liver metastases	24	6 or more	8 (20%)	

Data cutoff date: January 13, 2025

Abbreviations: ADCC: antibody-dependent cell-mediated cytotoxicity; AE: adverse event; ALT: alanine aminotransferase; BOR: best overall response; C#D#: Cycle # Day #; CEA: Carcinoembryonic Antigen; CRC: colorectal cancer; ctDNA: Circulating Tumor DNA; CTLA-4: cytotoxic T-Lymphocyte Associated Protein 4; DCR: disease control rate; dMMR: deficient mismatch repair; ECOG PS: Eastern Cooperative Oncology Group Performance Status; Fc: fraction crystallizable; FcyR: fraction crystallizable gamma receptor; irAE: immune-related adverse event; mAb: monoclonal antibody; MMP: matrix metalloprotease; MSI-H: microsatellite instability-high; MSS: microsatellite instability-high; MSS: microsatellite stable; NSCLC: non-small cell lung cancer; ORR: objective response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 3 weeks; SOD: sum of diameters; (i)RECIST: (immune) Response rate; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 4; PD-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 4; PA-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 4; PA-L1: programmed death receptor ligand 1; PR: partial response; Q3W: every 4; PA-L1: programmed death receptor ligan regulatory T-cell.



Total (N=40)	
23	
17	
6	
8	
3	

- Vilastobart (XTX101) is a novel tumor-activated, high affinity binding, Fc-enhanced anti-CTLA-4 mAb that is designed to focus activity
- Clinical data to date suggest that vilastobart has a differentiated safety profile from systemically active anti-CTLA-4, consistent with tumor-selective
- In Phase 1C, one patient with MSS CRC has an ongoing PR (confirmed) with resolution of liver metastases
- The combination of vilastobart and atezolizumab showed anti-tumor activity in MSS CRC where previously PD(L)-1 inhibitors and first generation anti-
- 3 PRs (2 confirmed, 1 pending confirmation) in patients with MSS CRC without liver metastases:
- 1 ongoing response with normalization of CEA accompanied by undetectable ctDNA following treatment
- An additional MSS CRC patient without liver metastases had a 24% tumor reduction at their initial 9-week assessment and is ongoing on therapy
- In Phase 2, the combination of vilastobart (100 mg Q6W) and atezolizumab (1200 mg Q3W) has been observed to be generally well-tolerated in patients

- These initial data support the further development of the combination of vilastobart and atezolizumab in patients with MSS CRC

Combination for Vilastobart (100 mg Q6W) and Atezolizumab (1200 mg Q3W)

Combination of Vilastobart (XTX101) and Atezolizumab Demonstrated Anti-Tumor Activity in MSS CRC Patients

27% ORR in Patients With MSS CRC Without Liver Metastases[‡]

- 40 patients with MSS CRC enrolled in ongoing Phase 2
- 18 patients response-evaluable with at least 1 scan reported

Best Response	Without Liver Metastases (n = 11 response-evaluable)	With Liver Metastases (n = 7 response-evaluable)
PR	3 [‡]	0
SD	3	1
ORR	27% [‡]	0%
DCR*	55%	14%

‡ Includes 2 confirmed PRs (see Patient A and Patient B vignettes) and 1 unconfirmed PR (pending confirmation, see Patient C

* DCR is defined as PR or SD through the first on treatment imaging scan as defined by the protocol (~9 weeks)

16 Weeks from First Dose Combination of Vilastobart (XTX101) and Atezolizumab Was

Generally Well-Tolerated in Phase 2


- 6 patients experienced Grade 3/4 TRAEs (related to vilastobart or atezolizumab)
- Only 2 Grade 4 TRAEs (thrombocytopenia and neutropenia, 1 each)
- No Grade 5 TRAEs

AE Category / Term All TRAEs with ≥10% incidence or Grade 3/4 TRAE with ≥ 5
Fatigue
Diarrhea
Infusion related reactions
Related to vilastobart
Related to atezolizumab
Pyrexia
ALT increased
AST increased
Colitis
Vilastobart dose reduction due to AE*
Treatment discontinuation due to TRAE ^A
TRAEs are related to vilastobart or atezolizumab

Dose reduction of atezolizumab is not permitted per protocol Reflects discontinuation of both vilastobart and atezolizumat

Non-laboratory Grade 3 TRAEs not included in the table above consisted of: maculopapular rash and febrile neutropenia in 1 patient; lower gastrointestinal hemorrhage in 1 patient with thrombocytopenia;

and 1 patient with Triple M overlap syndrome (myocarditis, myositis and myasthenia gravis).



. Bullock et al. ESMO GI 2023 Davar et al. ESMO IO 2023

References

4. Davar et al, SITC 2024, data updated as of Jan 6th, 2025 5. Sahin et al, 2022 ASCO Educational Book



1. Jenkins et al., J Immunother Cancer 2023 Dec 12;11(12):e007785